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879-3 The Ef fect  o f  Intra AorUc Balloon Pumping on Coronary 
and Tranamitral Flow 
Ashraf W. Khir. Susanna Price, Michael Y. Henein, Kim H. Parker, John Pepper, Royal 
Brompton Hospital London, United Kingdom. 
Background: The Intre Aortic Balloon Pump (IABP) is the most widely used form of tam- 
porary cardiac assist. The effect of diastolic counter pulsation on left ventricular (LV) fill- 
ing has not been investigated. 
Methods: We recorded left anterior descending coronary artery and transmitral flow 
velocities in 20 patients in the intensive care unit, following coronary artery bypass sur- 
gery, using transesophageal Doppler echo approach. The pump (Datascopa, 98XT) was 
set to full augmentation and the timing was adjusted for the inflation to start at the time of 
aortic valve closure and the deflation at the peak R wave of the electrocardiogram. 
Recordings were made at different pumping rates; 1:1, 1:2, 1:3, and when the pump was 
turned off, leaving a minimum of 5 minutes between recordings to allow for the retum to 
basal values. 
Results: Peak coronary diastolic flow velocities increased significantly with IABP 1:1 
(25±6 %, p<0.001), 1:2 (22±4%, p<0.001), and 1:3 (20±4%, p<0.001) compared to its 
value with the pump turned off. LV early diastolic filling velocities, E wave, also increased 
significantly with IABP 1:1 (35±7%, p< 0,001), 1:2 (31±5 %, p<0.001), and 1:3 (28±4%, 
p<0.001) compared to its value with the pump turned off. The change in diastolic coro- 
nary flow velocity with 1:1 balloon pumping correlated closely with the change of the E 
wave velocity (r=0.74. p<0.001). 
Conclusion: IABP significantly increases diastolic coronary flow and LV early diastolic fill- 
ing velocities. Although the formal is epicardial and the latter is intracardial the close rela- 
tionship between the two suggests an overall improvement in diastolic function with 
IABP. 
4:45 p.m. 
879-4 Init ial  and Prolonged Hemodynamic Ef fects  of  
Intreaort ic  Balloon Support in Ventricular Septal Defect  
Complicating Acute Myocardial Infarction 
HOlder Thiele. Bernward Lauer, Enno Boudriot, Gerhard Schuter, University of Leipzig - 
Heart Center, Leipzig, Germany. 
Background: Immediate surgical repair of ventricular septal defect (VSD) complicating 
acute myocardial infarction is associated with high mortality, Preoperative use of an 
intraaortic balloon pump (IABP) is routinely recommended to achieve hemodynamic sta- 
bilization, which permits preoperative diagnostic examinations or even delayed surgical 
repair. However, the hemodynamic effects of IABP support are deemed to be short last- 
ing and therefore long-term support is not recommended, 
Methods and results: An IABP was implanted preoperatively from 12/1997 to 09/2001 in 
20 consecutive patients with infarct-related VSD (11 men, 9 women, mean age 70±11, 
range 46-89), Effective cardiac output (I/mini, left-to-right-shunt (I/mini and the shunt flow 
ratio were calculated by the method of Fick pre and post intraaortic balloon counterpulsa- 
tion and at daily follow-up with pump on and off in those undergoing delayed surgical 
repair (n=9). Effective cardiac output improved from 3.6±1.3 I/min to 4.2¢1,3 I/rain 
(p<0,001), left-to-right-shunt and shunt flow ratio were reduced from 7,3±3,5 and 3.1±0.9 
I/rain to 5.6±.3.3 and 2.5¢0.7 I/min immediately after IABP insertion (both p<0,001), 
respectively. At foUow-up hemodynamic improvements were sustained and no deteriora* 
tions occured. Mortality in patients with early (day 1-2) operation was 71% and with 
delayed surgery (day 8-25) 22% (p<0.05), respectively. 
Conclusion: In patients with infarct related VSD IABP support provides an immediate and 
sustained hemodynamic improvement resulting in an enhanced effective cardiac output 
and a reduced left-to-right-shunt and shunt flow ratio. This results in hemodynamic stabi- 
lization in at least some patients, which may result in an improved outcome. 
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895-1 P lasma N-Terminal pro-BNP Predicts the Occurrence of 
Major  Cl in ical  Events  in Severe Chronic Heart Failure: 
Results of  a Subetudy  of  the  COPERNICUS Trial 
Franz S. Hartmann. Gert Richardt, Milton Packer, Andrew J. Coats, Michael B. Fowler, 
Henry Krum, Paul Mohacsi, Jean L. Rouleau, Michel Tendera, Alain Castaigne, Matthias 
Baumann, Juergec Trawinski, Silke Horsch, Ildiko Amann-Zalan, Hugo A. Katus, 
Universitaetsklinik Luebeck, Luebeck, Germany. 
Background: The measurement of cardiac natriuretic peptides has been proposed as a 
tool to monitor the progression of heart failure (HF), but its utility in this regard may be 
biased by changes in these peptides induced by changes in volume status. 
Methods: Baseline plasma concentrations of NT-proBNP were measured using a newly 
developed sandwich ELISA in a subgroup of 844 men and 204 women with symptoms at 
rest or on minimal exertion who were enrolled in the European part of the COPERNICUS 
study and were randomized to placebo (PBO, n=524) or carvedilol (CRV, n=524) for up 
to 29 months. Values of NT-proBNP were markedly increased despite the requirement 
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that patients be euvolemic before the start of treatment (mean ± SD = 579 ± 822 pmol/L, 
median = 323 pmol/L). By univariata and multivariate Cox regression, NT-proBNP (ana- 
lyzed as a continuous or categorical variable) was found to be a powerful predictor of all- 
cause mortality and other major clinical events (see table), all P < 0.0001. Predictive 
value of NT-preBNP was similar when both PBO and CRV patients were analyzed sepa- 
rately. 
Conclusions: Cimuiating levels of NT-proBNP predict aU-cause mortality and major clini- 
cal events in patients with severe HF, even those who were clinically euvolemic. 
One-year event rates and risk ratios In PBO +CRV combined 
NT-proBNP NT-proBNP Risk ratio 95% C.I. 
<median >median 
All-cause mortality 6.2% 22.4% 3.13 1.94-5.07 
All-cause mortality or 33.9% 52.8% 1.96 1.56-2.48 
hospitalization for any reason 
All-cause mortality or 19.9% 41.9% 2.60 1.95-3.46 
cardiovascular hospitalization 
All-cause mortality or 16.4% 40.3% 3.11 2.27-4.27 
hospitalization for heart failure 
10:45 a.m. 
895-2 Head to Head Comparison of the Diagnostic Value of  
Bedside Measurement of B-Type Natrluretic Peptlde and 
Echocardlogrsphy in Patients With Acute Dyspnea 
Damien Looeart, Pascale Beyne, Pierre-Vladimir Ennezat, Carole Saudubray, Alain 
Cohen Solal, Beaujon Hosp#al AP-HP, Clichy, France. 
Background: The cause of acute dyspnea may be difficult to establish in an urgent-care 
setting. The aim of this study was to compare the diagnostic accuracy of bedside mea- 
surements of B-Type natriuretic peptide (BNP) and Doppler echocardiography in this set- 
ring. 
Methods: BNP was measured at admission by a rapid assay (Biosita Diagnostics, CA) 
before the onset of treatment, in 100 patients (70+~ years) presenting with severe dysp- 
nea in an emergency department. Doppler-echocardiogram was performed at the same 
time. Results were withheld from clinicians and were compared to the initial diagnosis 
and to the final diagnosis retrospectively established at discharge by a college of physi- 
cians 
Results: Final diagnosis was acute congestive left ventricular failure (CHF) in 72 
patients, pulmonary disease in 20, pulmonary embolism in 6 and other cause in 2, At the 
emergency department, CHF was overestimated in 8 patients and non-diagnosed in 6. 
BNP concentrations were 398-+32 pg/ml (55-1014) in CHF, 54±12 pg/ml (7-167) in pul- 
monary diseases and 147+72 pg/ml (9-390) in pulmonary embolism (p<0.01). Cut-off 
BNP value of 60 pg/ml was the most accurate for the diagnosis of CHF with negative and 
positive predictive values of 91 and 85% respectively. This low cut-off value ted to over- 
estimate the possibility of CHF and was due to low BNP levels (55 to 80 pg/ml) in 6 
patients presenting with flash pulmonary edema with short delay (< 2 hours) before 
admission, preserved systolic function and no previous history of CHF. Doppler analysis 
of mitral inflow had negative and positive predictive values of 97 and 93% respectively, 
considering that "restrictive' or "normalized' patterns were associated with CHF in this 
elderly population. However, this analysis was possible in only 74 patients because of 
tachycardia, arrhylhmia, pacing and 72 patients only were correctly diagnosed versus 88 
patients with BNP. 
Conclusion: Bedside echocardiography is more accurate than BNP to differentiate CHF 
from others causes in acute dyspnea. However, BNP appears as the most useful of the 
first-line diagnostic tools because mitral Doppler pattern is uninterprstable in numerous 
cases. BNP should be usecl with caution in flash pulmonary edema. 
11:00 a.m. 
895-3 P lasma BNP to Screen for Systolic Dysfunction in the 
Community: Importance of Using Age- end Sex-Speci f ic  
Part i t ion Values 
Marcaret M. Redfield, Richard J. Rodeheffer, Douglas W. Mahoney, Stevec J. Jacobsen, 
John C, Burnett, Jr., Mayo Clinic and Foundation, Rochester, Minnesota. 
Background: Studies suggest that systolic dysfunction (LVSD) is common in the com- 
munity. If plasma BNP is to be used to screen for LVSD, the level of BNP which is consid- 
ered abnormal (partition value) must be defined. As BNP is higher in females and 
increases with age in the absence of cardiovascular disease, age- and sex-specific parti- 
tion values may be needed to optimize its performance. In the current study, we exam- 
ined the sensitivity and specificity of BNP for detection of an ejection fraction (EF) <40% 
by age and sex in a population-based cohort. Methods: Randomly selected residents of 
Olmsted County, MN age _>45 yrs (n=2042) underwent echo and measurement of BNP 
(Biosite~ assay). Results: The value of BNP providing 75% specificity 
(BNP@75%Spec), the sensitMty/specificity (Sens/Spec) at that value and the area 
under the receiver operating curve (AUC) for detection of EF_<40% are shown for each 
age/sex strata (table, ND = no LVSD detected). 40 subjects (2.0%) had EF<40%. We 
also examined the use of a single partition value (53 pg/ml) yielding 75% specificity in the 
entire population and evaluated it within each age/sex strata. In contrast o the age- and 
sex-specific partition values (table), use of the single partition value resulted in poor sen- 
sitivity in the youngest (25% Males; ND Females) and poor specificity (50% Males; 29% 
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Females) in the oldest age groups. Conclusion: Use of age- and sex-specific partition 
values enhances the operating characteristics of BNP for detection of LVSD in the com- 
munity. 
BNP@75%Spec Sens/Spec AUC 
Males 45-54 yrs 17 pg/ml 75%/75% 0.88 
Females 45-54 yrs 33 pg/ml ND/75% ND 
Males 55-64 yrs 28 pg/ml 100%/75% 0.94 
Females 55-64 yrs 54 pg/ml 100%/75% 0.97 
Males 65-74 yrs 68 pg/ml 82%/75% 0.89 
Females 65-74 yrs 63 pg/ml 100%/75% 0.90 
Males => 75 yrs 174 pg/ml 78%/75% 0.89 
Females =>75 yrs 168 pg/ml 75%/75% 0.85 
11:15 a.rn. 
895-4 Ut i l i ty of Natriuretic Peptides for Detecting Left 
Ventricular Hypertrophy and Dysfunction: The 
Framingham Study 
Ramachandran S. Vasan. Martin G. Larson, Eric P. Leip, Emelia J. Benjamin, Thomas J, 
Wang, Patrica Sutherland, Peter W. Wilson, Daniel Levy, NHLBI's Framingham Heart 
Study, Framingham, Massachusetts, Boston University School of Medicine, Boston, 
Massachusetts. 
Background: Brain natriuretic peptide (BNP) and N-terminal atrial natriuretic peptide 
(NT-ANP) have been proposed as screening tests for left ventricular hypertrophy (LVH) 
and LV dysfunction. However, prior studies were limited by small samples and none com- 
pared the diagnostic performance of these peptides in men and women. 
Methods: We evaluated 3441 Framingham Study subjects (1823 women; mean age 59 
years) who attended a routine exam st which echocardiography was performed, and 
plasma SNP and NT-ANP estimated. We examined the contribution of peptide levels for 
detecting LVH, LV dysfunction (fractional shortening [FS}<0.3O), and severe LV dysfunc- 
tion (FS<O.22) by constructing sex-specific ROC curves for each outcome. 
Results: The areas under the ROC curve (AUC) for BNP were consistently higher for 
men compared with women for LVH and LV dysfunction, but not for severe LV dysfunc- 
tion (1"able). Performance characteristics of BNP values that yielded 0.95 specificity are 
shown in the Table. Both BNP and NT-ANP peptides performed well for excluding severe 
LV dysfunction (data for NT-ANP not shown). 
Conclusions: In our large community-based sample, performance of BNP and NT-ANP 
for detection of LV dysfunction and LVH differed between men and women. A high nega- 
tive predictive value for severe LV dysfunction indicates their potential utility for excluding 
severe LV dysfunction, These results can be used to determine the utility of neuropeptide 
screening for LVH and LV dysfunction in asymptomatic people. 
Diagnostic Performance of BNP 
LVH LV Dyefunctlon Severe LV 
Dysfunction 
Men Women Men Women Men Women 
AUC (95% Cl) 0.70 0.57 0.68 0.56 0.84 0.82 
(0.65-0.74) (0.54-0.60)** (0.64-0.72) (0.50-0.52)** (0.75-0.93) (0.61-1.6) 
Sensitivity* 0.30 0.12 0.25 0.t4 0.35 0.43 
PPV/NPV* 0.55/0.87 0.57/0.67 0.44/0.90 0.14/0.95 0.21/0.98 0.04/0.99 
* for specificity =0.95. ** p<0.01 for men vs women. PPV and NPV: positive and nega- 
tive predictive value 
11:30 a.m. 
895-5 A Rapid BNP Assay Accurately Diagnoses Left 
Ventricular Dysfunction and Heart Failure: A Multicenter 
Study 
Alan S. Maisel, Stacey J. Wieczorek, Robert Christenson, Steven Gottlieb, Thomas 
Rosano, David Hager, Alan Wu, San Diego VA Healthcare System, San Diego, 
California, Hartford Hospital, Hartford, Connecticut. 
Background: B-Type Natriuretic peptide (BNP), a protein released from the left ventricle 
in response to volume and pressure ovedoad, has emerged as the first whole blood 
marker for the identification of patients with congestive heart failure (CHF). The 
increased awareness and clinical significance of BNP has warranted the develpoment of 
the first point-of-care assay to rapidly identify and determine severity of CHE Objective: 
To assess the performance of a point-of-care-assay to diagnose and evaluate the sever- 
ity of CHI£ Methodology: Through a prospective, multi-center trial (5 centers), whole 
blood was collected from 1053 patients during the years of 1999-2000. Participants were 
divided into subgroups: normal (n=473), hypertension but no CHF (n=168), and CHF 
(n=804), divided by New York Heart Association (NYHA). Results: The coefficient of vari- 
ation (CV) for intra-assay precision of the test was 9.5% with an analystical sensitivity of 
5.0 pg/ml. 100% of samples were stable up to 8 hours at 4 degrees. Minimum stability at 
room temperature was 4 hours. Patients with no CHF had BNP levels of 9.3 pg/ml and 
was not different from patients with hypertension an no CHF. The median BNP value was 
higher in normal females (12.8) than in males (5.4 pg/ml, P < 0.001) Median BNP levels 
increased with age for both genders. BNP levels increased with severity, but because of 
overlap, could not predict individual NYHA classes. Median BNP levels, for NYHA I-IV 
were 83 pg/ml, 235 pg/ml, 459 pg/ml, and 1119 pg/ml, respectively. The receiver oper- 
ated characteristic curve for all CHF classes was 0.97 ( P< 0.001). Using a decision 
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threshold of 100 pg/ml, the assay demonstrated 82% sensitivity and 99% specificity for 
distinguishing controt and CHF subjects. Conclusion: BNP concentrations obtained from 
whole blood samples are useful in the diagnosis of CHF and staging the severity of dis- 
ease. 
11:45 a.m. 
895-6 Primary Results of the BNP Multinational Study: B-Type 
Natrluretic Peptide in the Emergency Diagnosis of Heart 
Failure 
Alan S. Maisel. Radmila Kazanegra, James McCord, Richard M. Nowak, Judd E. 
Hollander, Phillippe Duc, Gabriel Steg, Torbjorn Omland, Arne Westheim, William T. 
Abraham, Alan B. Storrow, Sumant Lamba, Alan H. Wu, Peter A. McCullough, BNP 
Multinational Study Investigators, University of California, VA Medical Center, San Diego, 
California, University of Missouri, Truman Medical Center, Kansas Ci~ Missouri. 
Background. B-type natriuretic peptide (BNP) is released from ventricular myocytes in 
response to wall tension and has been approved as an aid in the diagnosis of congestive 
heart failure (CHF). We sought to determine the diagnostic utility of BNP in the emer- 
gency department (ED) evalution of dyspnea in a broad spectrum of patients. 
Methods, The BNP Multinational Study was a seven-canter, prospective cohort study of 
1586 patients who presented to the ED with acute dyspnea and had BNP measured with 
a point-of-care device upon ardval. The gold-standard for CHF was adjudicated by two 
independent cardiologists, blinded to BNP results, who reviewed all clinical data and 
standardized CHF scores (NHANES and Framingham). 
Results. Baseline characteristics: mean age 64.4 years, mate 55.8%, female 44.5%, 
Caucasian 49.2%, African American 44.5%, and other race 6.3%. The final diagnosis 
was CHF in 804 (50.7%), a history of CHF but dyspnea due to noncardiac causes in 138 
(8.7%), and not CHF in 644 (40.6%), with mean BNP levels displayed (see figure). The 
most common other diagnoses were asthma and emphysema. The area under the 
receiver operator characteristic curve for the determination of CHF was 0.90, 95% CI 
0.89-0.92. The diagnostic accuracy for BNP was 82.7% for the correct diagnosis at at 
cutoff level of 125 pg/ml. 
Conclusions. In patients with acute dyspnea, using a point-of-care device in the ED, 
measurement of BNP has a high degree of diagnostic accuracy in establishing the diago- 
sis of CHF. 
Mean BNP Upon ED ,a.trival 
n < 0 0001 for all pa l~se  (ompansons 
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